首页> 外文OA文献 >Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy

【2h】

Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy

机译：关于淋巴细胞活化基因3和编程死亡-1 /编程死亡-1配体-1对癌症免疫疗法的研究进展：这种潜在更有效的免疫治疗策略的临床前和临床证据

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Yihang Qi; Li Chen; Qiang Liu; Xiangyi Kong; Yi Fang; Jing Wang;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management [J] . John Shen, Jason Chang, Melody Mendenhall, Therapeutic advances in medical oncology. . 2018,第3期

机译：由抗程序性细胞死亡1（PD-1）和抗程序性细胞死亡配体1（PD-L1）免疫疗法引起的多种皮肤不良反应：临床特征和管理
2. Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis [J] . Niglio Scot A., Jia Rachel, Ji Jiayi, European urology . 2019,第6期

机译：编程死亡1或编程死亡配体-1抗铂抗性转移性尿路上皮癌患者的障碍：系统审查和荟萃分析
3. Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies [J] . Lu-Lu Yang, Yi-Long Wu Lung cancer management. . 2014,第2期

机译：肺癌免疫疗法的最新进展：抗程序性细胞死亡1 /程序性死亡配体1抗体
4. Developing Strategies: Immunotherapies and Programmed Cell Death 1 Inhibition [C] . David F. McDermott Genitourinary Cancers Symposium . 2013

机译：开发策略：免疫治疗和编程细胞死亡1抑制
5. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. [D] . 野﨑, 結 2019

机译：PD-L1特异性辅助性T细胞表现出有效的抗肿瘤反应：针对头颈部鳞状细胞癌中PD-L1的癌症免疫疗法的新策略。
6. Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy [O] . Yihang Qi, Li Chen, Qiang Liu, 2020

机译：关于淋巴细胞活化基因3和编程死亡-1 /编程死亡-1配体-1对癌症免疫疗法的研究进展：这种潜在更有效的免疫治疗策略的临床前和临床证据
7. Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer [O] . Yuichiro Ohigashi, Masayuki Sho, Yukishige Yamada, 2005

机译：编程死亡-1配体-1和编程死亡-1配体-2在人食管癌中的临床意义
8. CTLA-4 Blockade-Based Immunotherapy in Prostate Cancer [R] . Rini, B. I. 2007

机译：基于CTLa-4阻断的前列腺癌免疫治疗

Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy

著录项

引文网络

相似文献

相关主题

期刊订阅